NRX Pharmaceuticals Says Mid-Stage Trial Shows BriLife COVID-19 Vaccine May Have Potential Against Delta Coronavirus Variant
NRX Pharmaceuticals Says Mid-Stage Trial Shows BriLife COVID-19 Vaccine May Have Potential Against Delta Coronavirus Variant
NRX制药公司表示，中期试验显示BriLife新冠肺炎疫苗可能具有对抗Delta冠状病毒变异株的潜力
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册